Recently, the EGFR/MET-bispecific monoclonal antibody amivantamab was approved by the Food and Drug Administration (FDA) for NSCLC patients with EGFR ex20ins, based on an ORR of 40% and a mPFS of 8.3 months (Park et al., 2021). This evidence concerns the gene MET and non-small cell lung carcinoma.